Transaction DateRecipientSharesTypePriceValue
19th October 2020Mark Alan Goldberg5,455Exercise of derivative$19.53$106,536.15
19th October 2020Mark Alan Goldberg5,455Open or private sale$105.00$572,775.00
16th October 2020Kate Haviland3,125Open or private sale$101.56$317,375.00
16th October 2020Kate Haviland13,334Exercise of derivative$36.05$480,690.70
16th October 2020Kate Haviland3,009Open or private sale$102.53$308,512.77
16th October 2020Kate Haviland7,200Open or private sale$100.55$723,960.00
7th October 2020Jeffrey W. Albers5,000Open or private sale$99.17$495,850.00
7th October 2020Jeffrey W. Albers5,000Exercise of derivative$8.80$44,000.00
7th October 2020Mark Alan Goldberg5,454Open or private sale$100.00$545,400.00
7th October 2020Mark Alan Goldberg5,454Exercise of derivative$19.53$106,516.62
Blueprint Medicines
Blueprint Medicines logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Blueprint Medicines Corp. focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in 2008.


Ticker: BPMC
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1597264
Employees: 383
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $289 M (0%)
Inventory, Net: $4 M (0%)
Assets, Current: $568 M (9%)
Property, Plant and Equipment, Net: $37 M (0%)
Other Assets, Noncurrent: $8 M (-18%)
Assets: $817 M (15%)
Accounts Payable, Current: $6 M (16%)
Accrued Liabilities, Current: $84 M (0%)
Liabilities, Current: $105 M (-1%)
Other Liabilities, Noncurrent: $9 M (9%)
Liabilities: $236 M (-2%)
Common Stock, Value, Issued: $54 Th (10%)
Common Stock, Shares, Issued: $54 M (10%)
Retained Earnings (Accumulated Deficit): $1 B (24%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-55%)
Stockholders' Equity (Parent): $581 M (0%)
Liabilities and Equity: $817 M (15%)
Cost of Revenue: $127 Th (-15%)
Research and Development: $91 M (-48%)
Other Income, net: $2 M (-63%)